Inhibitors of myeloperoxidase
AssigneeAstraZeneca AB
InventorsTORD INGHARDT, EVA-LOTTE LINDSTEDT, ULRIK JURVA, NIDHAL SELMI
Life of this patent
Estimating the term…
Loading patent…
AssigneeAstraZeneca AB
InventorsTORD INGHARDT, EVA-LOTTE LINDSTEDT, ULRIK JURVA, NIDHAL SELMI
Estimating the term…
The specification generally relates to compounds of Formula (I), (Ia), and (Ib): and pharmaceutically acceptable salts thereof, where X, Y1, Y2, Y3, Y4, and Y5 and X1, X2, r, and q, have any of the meanings defined herein, together with compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO, and are thereby particularly useful in the treatment or prophylaxis of diseases or conditions in which modulation of the activity of the enzyme myeloperoxidase (MPO) is desirable, including diseases with inflammatory, cardiovascular, respiratory, renal, hepatic and/or neurological components, as well as neutrophilic driven diseases.
A Compound of formula (I)
(canceled)
(canceled)
6-9. (canceled)
11-14. (canceled)
-18. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-38. (canceled)
(canceled)
(canceled)
-53. (canceled)
55-64. (canceled)
-78. (canceled)
Dependencies are inferred from the claim text.